As Fig. 1c showed, SNHG6 was significantly upregulated in most malignancies, such as breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), etc. Especially, SNHG6 was notably upregulated in NSCLC tumor tissues as well (Fig. 1d, unpaired samples, Normal = 108 vs Tumor = 1037, P < 0.001; Fig. 1e, 106 paired samples, P < 0.001). Here, SNHG6 is linked to cholangiocarcinoma.